Staffers are set to move to their new digs in east London in the middle of next year, shortly the EMA is scheduled to leave a neighboring building.
Check out the rest of Thursday's news of note.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva.
Officials at the EMA must now allay concerns their meetings with sponsors introduce a source of bias into their decision-making.
The third late-phase success sets Paratek up to file for approval, although incidence of vomiting and nausea cast a shadow over the data.
Check out today's best of the rest of biopharma news.
CymaBay has taken a look at its ongoing midstage test for its liver med seladelpar, and is happy with what it sees.
Officials are making the cash available to implement recommendations the U.K. sees establishing it as the first port of call for drug development.
Officials knocked back the filing after phase 3 data linked the sclerostin-targeting antibody to an increased risk of cardiovascular adverse events.
Allena Pharma has been granted orphan status by the FDA for a drug to treat primary hyperoxaluria.